Japan’s Teijin Pharma Gout Drug TMX-67 Gains EMEA Positive Opinion
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma received a positive opinion from the Europe Medicines Agency for gout drug TMX-67 through its licensee for Europe, Ipsen. An oral, once-daily drug, TMX-67 (febuxostat) is a novel xanthine oxidase inhibitor with a different structure than allopurinol, the only available gout drug developed 40 years ago. Teijin views IMX-67 as a way to expand into overseas markets. It also plans to resubmit an application for approval in Japan. Additional Phase III trials are being conducted in the U.S., and trials are also being conducted in Korea. After obtaining European approval, Ipsen plans to sell the drug under the name Adenuric.(Click for more-Japanese language